Key points:
NJOY accuses Juul of infringing on e-cigarette patents, but Juul receives a non-infringement ruling.
The United States International Trade Commission (ITC) supports the preliminary ruling after review.
ITC refused to take a stance on the economic aspects and decided to support Juul.
According to a report by Tobaccoreporter on March 5th, the U.S. International Trade Commission (ITC) has ruled in favor of Juul Labs in a patent infringement case, finding no infringement.
In January 2025, Administrative Law Judge Doris Johnson Hines ruled that Juul Labs' e-cigarette products did not violate Section 337 of the Tariff Act. Altria claimed that these products infringed on two patents related to e-cigarette technology, but the judge did not agree.
In a three-page decision, the International Trade Commission (ITC) reviewed a non-infringement finding and made modifications to the judge's initial ruling by modifying the citations. The decision stated that NJOY failed to provide an economic example of meeting domestic industry requirements, which would require the complainant to prove significant investments in products protected by patents. The ITC did not express a position on the economic aspect and also refused to review the remaining decisions, including the judge's conclusion that Juul did not violate Section 337 of the Tariff Act.
According to court documents, the Juul products being investigated by the ITC are classified as "electronic nicotine delivery systems" and related pods, pod components, including atomizers, sub-components, device sub-components, and chargers.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
